Global English
Global English Global English Poland polski Czechia Český Italy Italiano Kazakhstan Қазақ Slovakia Slovenský Spain Español Ukraine Українськa Uzbekistan Ўзбекча Vietnam Tiếng việt
Popular searches InnovationsAbout AdamedBusiness DevelopmentAdamed worldwideResearches
x

Business Development

Adamed has gone international

Adamed joined the globalinnovation race in the early 2000s and has consistently strengthened its position on international markets. Now Adamed is a truly international organization, with approximately 2,700 staff in 8 countries. 

 

We sell our products B2B on dozens of markets worldwide, and our product portfolio we offer is a range of nearly 900 products (so-called SKUs) in Poland and abroad. We sell our products in two business models:

Out-licensing to our business partners, where the intellectual property rights to the products remain in Poland.
Building our own sales and marketing channels, while at the same time promoting the Adamed brand in new countries.

 

License-out

The Adamed Business Development Team is a group of professionals responsible for the sale of Adamed products on global markets.

We are open to different business partnership models, including out-licensing, product distribution, joint development of new products, and contract manufacturing.

We provide comprehensive support on regulatory and intellectual property matters, market entry strategy for offered products, and open partnership. All of these aspects are aimed at ensuring that all new products are successfully launched with minimal risk while maintaining competitive prices for our customers.

Our business partners are provided with a registration dossier for all finished formulations in e-CTD format that meets the most stringent requirements of the national regulatory agencies in their respective countries, including the requirements for stability testing for all climate zones. Our products are manufactured at state-of-the-art facilities certified for compliance with GMP standards, both European and those applicable in other countries, including Saudi Arabia, Turkey, and Australia. Having vast experience in business development and out-licensing, the team establishes top-level partnerships based on a win-win strategy as a guarantee for long-lasting, stable cooperation with our business partners based on mutual trust.

Cardiology
Central nervous system
Diabetology
Gynaecology and urology
Oncology
Pulmonology and allergology
Other therapy groups
Over the counter (OTC)
Cardiology

  • AMLODIPINE 5mg; 10mg, tablets

  • CANDESARTAN + AMLODIPINE + HCTZ 16mg/5mg/12,5mg; 16mg/10mg/12,5mg, capsules (NEW)

  • CILOSTAZOL 50mg; 100mg, tablets

  • DABIGATRAN 75mg; 110mg; 150mg, capsules (NEW)

  • EPLERENONE 25mg; 50mg, coated tablets

  • EZETIMIBE 10mg, tablets

  • EZETIMIBE + ROSUVASTATIN 10mg/5mg; 10mg/10mg; 10mg/20mg, tablets (NEW)

  • EZETIMIBE + ROSUVASTATIN 10mg/5mg; 10mg/10mg; 10mg/15mg; 10mg/20mg; 10mg/30mg; 10mg/40mg, tablets

  • PERINDOPRIL TERT-BUTYLAMINE + AMLODIPINE 4mg/5mg; 4mg/10mg; 8mg/5mg; 8mg/10mg, tablets

  • RAMIPRIL + AMLODIPINE 2,5mg/5mg; 5mg/5mg; 5mg/10mg; 10mg/5mg; 10mg/10mg, capsules

  • RAMIPRIL + AMLODIPINE BESYLATE + HCTZ 5mg/5mg/25mg; 10mg/5mg/25mg; 5mg/5mg/12,5mg; 10mg/10mg/25mg, capsules

  • RAMIPRIL + BISOPROLOL 2,5mg/1,25mg; 2,5mg/2,5mg; 5mg/2,5mg; 5mg/5mg; 10mg/5mg; 10mg/10mg, capsules (NEW)

  • RANOLAZINE 375mg; 500mg; 750mg, extended release tablets (NEW)

  • RIVAROXABAN 2,5mg; 10mg; 15mg; 20mg, coated tablets (NEW)

  • ROSUVASTATIN 5mg; 10mg; 15mg; 20mg; 30mg; 40mg, coated tablets

  • ROSUVASTATIN + ACETYLSALICYLIC ACID 5mg/100mg; 10mg/100mg; 20mg/100mg, capsules

  • ROSUVASTATIN + AMLODIPINE 10mg/5mg; 10mg/10mg; 20mg/5mg; 20mg/10mg, capsules

  • TELMISARTAN + ROSUVASTATIN 40mg/10mg; 40mg/20mg; 80mg/10mg; 80mg/20mg, coated tablets (NEW)

Central nervous system
  • B1 + B6 + B12 Vitamin Complex 150mg/50mg/0,2mg, coated tablets (NEW)  
  • DULOXETINE 30mg; 60mg, enteric-coated tablets 
  • MIANSERIN 60mg; coated tablets 
  • OLANZAPINE5mg; 10mg, tablets           
  • OLANZAPINE ODT 5mg; 10mg; 15mg; 20mg, orodispersible tablets
  • PREGABALIN 25mg, 50mg; 75mg; 100mg; 150mg; 200mg; 225mg; 300mg, capsules
Diabetology
  • LINAGLIPTIN, 5mg, coated tablets (NEW)
  • SITAGLIPTIN 25mg; 50mg; 100mg, coated tablets
  • SITAGLIPTIN + METFORMIN XR 50mg/500mg; 50mg/1000mg; 100mg/1000mg; extended release tablets
Gynaecology and urology
  • FINASTERIDE + TADALAFIL, 5mg/5mg, tablets (NEW)
  • PROGESTERONE, 50mg, 100mg, 200mg, vaginal tablets
  • SILDENAFIL 25mg, 50mg, 100mg, coated tablets
  • SOLIFENACIN + TAMSULOSIN OCAS® 6mg/0,4mg, extended release tablets
  • TAMSULOSIN OCAS® 0,4 mg, extended release tablets
  • TRANEXAMIC ACID 1000mg; 500mg, tablets (NEW)
Oncology
  • ABIRATERONE 250mg; 500mg, coated tablets
  • BORTEZOMIB 3,5mg, vial
  • IMATINIB 100mg; 400mg, capsules
  • SUNITINIB 12,5mg; 25mg; 37,5mg; 50mg, capsules
Pulmonology and allergology
  • LEVOCETIRIZINE 5mg, coated tablets
  • LEVOCETIRIZINE 0,5mg/ml, oral solution
Other therapy groups
  • AZITHROMYCIN 250mg; 500mg, coated tablets
  • DEXAMETHASONE 4mg; 8mg; 20mg, tablets
  • FLUDROCORTISONE 0,1mg, tablets
  • NAPROXEN 500mg, enteric-coated tablets
  • RISEDRONATE SODIUM 35mg; 75mg, coated tablets
Over the counter (OTC)
  • BIOTIN 10mg, tablets
  • CYTISINE 1,5mg, coated tablets
  • CYTISINE 1,5mg, oral solution (spray) (NEW)
  • DROTAVERINE + METAMIZOLE + CAFFEINE 40mg/400mg/60mg; 80mg/400mg/60mg, tablets
  • FURAZIDIN 50mg; 100mg, tablets
  • HYMECROMONE 400mg, tablets
  • INOSINE PRANOBEX 312,5mg/ml powder for oral suspension (NEW)
  • METAMIZOLE 500mg, tablets
  • MINOXIDIL 5%, foam (NEW)
  • NAPROXEN SODIUM 220mg, capsules
  • SILDENAFIL 25mg; 50mg, tabletki powlekane (also available as RX) (NEW)
  • TRANEXAMIC ACID 500mg, tablets (also available as RX) (NEW)

In-Licensing & Business Development Department

Katarzyna Chądzyńska-Tragarz
License-In & Codevelopment Contracts Department Director
katarzyna.chadzynska@adamed.com

Out-Licensing Department 


Sebastian Gromek
Director Licensing-Out & Commercial Alliances Management
sebastian.gromek@adamed.com